Paragon Care Limited (PGC) AI Stock Analysis

• Market Cap: €695.23M
• Dividend Yield: N/A
• Average Volume (3M): 385.89K
• Price to Earnings (P/E): 33.6
• Beta (1Y): 1.08
• Revenue Growth: 1387.97%
• EPS Growth: -1.57%
• Country: AU
• Employees: 400
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Distribution
• EPS (TTM): 0.01
• Shares Outstanding: 1,655,305,400
• 10 Day Avg. Volume: 171,256
• 30 Day Avg. Volume: 385,894
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €0.54
• Price Target Upside: 28.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Paragon Care Limited's overall score reflects its robust financial performance and effective cash flow management, despite profitability challenges. The technical indicators show short-term positive momentum, but caution is advised due to potential overbought signals. Valuation concerns, with a high P/E ratio and no dividend yield, slightly dampen the overall attractiveness.

Paragon Care Limited Business Overview & Revenue Model

Company Description

Paragon Care Limited (PGC) is a leading provider of medical equipment, devices, and consumables, primarily serving the healthcare sector across the Asia-Pacific region. The company operates in several key areas, including diagnostics, life sciences, and acute and aged care. Paragon Care offers a wide range of products and services designed to enhance the delivery of healthcare, including surgical instruments, diagnostic imaging equipment, and medical IT solutions.

How the Company Makes Money

Paragon Care Limited generates revenue through the sale of medical equipment, devices, and consumables to hospitals, healthcare providers, and other medical institutions. The company also offers maintenance and support services for its products, providing an additional revenue stream. Key revenue streams include direct sales of their diverse range of healthcare products, long-term supply contracts, and partnerships with leading international manufacturers, which enable Paragon Care to distribute high-quality, innovative products across the Asia-Pacific region. The company's strategic acquisitions and partnerships help expand its product offerings and market reach, contributing significantly to its financial performance.

Paragon Care Limited Financial Statement Overview

Summary

Paragon Care Limited demonstrates a solid financial performance with consistent revenue growth and effective cash flow management. While the company faces some profitability challenges, its balanced leverage and cash generation capabilities provide a stable foundation for future growth.

Income Statement

Paragon Care Limited has shown a stable revenue growth trajectory over recent years with a revenue increase in the TTM period. Despite a dip in net income, the company maintains solid profit margins with a Gross Profit Margin of 5.93% and an EBIT Margin of 1.63% in the latest annual report. However, the decline in EBITDA and net income in the latest TTM period suggests profitability challenges remain.

Balance Sheet

The company demonstrates a moderate Debt-to-Equity Ratio of 0.86, reflecting a balanced leverage level. A positive Return on Equity of 2.87% indicates effective use of equity, albeit lower compared to previous periods. The Equity Ratio is 25.81%, showing a stable financial structure with room for improvement.

Cash Flow

Paragon Care Limited has exhibited strong cash flow management with significant Free Cash Flow growth, albeit from a negative base in the previous year. The Operating Cash Flow to Net Income ratio of 5.30 indicates strong cash generation relative to accounting profit, enhancing financial flexibility.

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
2.97B	307.63M	237.62M	235.84M	231.69M
	Gross Profit
176.07M	51.68M	36.58M	33.41M	78.76M
	EBIT
28.44M	26.41M	15.34M	13.98M	4.08M
	EBITDA
43.18M	37.07M	23.27M	20.18M	-62.09M
	Net Income Common Stockholders
8.38M	10.76M	6.63M	8.28M	-77.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
19.94M	22.60M	46.20M	33.20M	24.50M
	Total Assets
1.13B	448.52M	438.44M	291.92M	292.17M
	Total Debt
251.83M	122.14M	131.26M	113.01M	115.03M
	Net Debt
231.88M	99.54M	85.06M	79.81M	90.52M
	Total Liabilities
838.97M	196.56M	196.31M	170.40M	179.89M
	Stockholders Equity
291.92M	242.85M	235.82M	121.52M	112.28M
Cash Flow		Free Cash Flow
25.14M	-3.30M	14.42M	22.18M	-1.98M
	Operating Cash Flow
44.45M	17.75M	19.03M	27.46M	5.29M
	Investing Cash Flow
-19.52M	-31.75M	7.07M	-18.80M	-11.40M
	Financing Cash Flow
-5.95M	-10.00M	-11.93M	32.00K	-3.60M

Paragon Care Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PGC, the sentiment is Neutral. The current price of 0.42 is above the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.42, and below the 200-day MA of 0.46, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.69 is Neutral, neither overbought nor oversold. The STOCH value of 56.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:PGC.

Paragon Care Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SHL	73 Outperform	AU$12.56B	22.85	6.86%	4.09%	10.15%	6.20%
ANN	71 Outperform	$4.53B	25.08	6.45%	2.46%	16.30%	1.08%
COH	68 Neutral	$17.48B	47.61	20.61%	1.61%	6.35%	5.97%
PGC	67 Neutral	€695.23M	33.60	6.68%	―	1387.97%	-1.57%
CSL	64 Neutral	$121.28B	29.85	15.38%	1.76%	8.00%	9.09%
RHC	55 Neutral	$7.88B	963.20	0.52%	2.33%	7.25%	-99.04%
Sector *	52 Neutral	$5.23B	3.70	-41.86%	2.84%	16.58%	-0.16%

Paragon Care Limited Corporate Events

Paragon Care Limited Updates Securities Trading Policy

Paragon Care Limited has announced a revision to its Securities Trading Policy, aligning with ASX Listing Rule 12.10. This update reflects the company’s commitment to maintaining robust corporate governance practices. The revised policy is accessible on the company’s website, underscoring Paragon Care’s dedication to transparency and regulatory compliance, which is crucial for its stakeholders and market positioning.

Paragon Care Appoints New Independent Non-Executive Director

Paragon Care Limited has appointed Peter Egglestone as an independent Non-Executive Director, effective 20 March 2025. With over 25 years of leadership, financial, and commercial experience, Egglestone’s expertise is expected to be a valuable asset as the company continues to execute its strategic initiatives and strengthen its market position.

Paragon Care Director Increases Stake with Share Acquisition

Paragon Care Limited announced a change in the director’s interest, with Director Carmen Riley acquiring 100,000 additional ordinary shares through an on-market trade, bringing her total to 300,000 ordinary shares. This acquisition reflects a significant increase in personal investment by a key company leader, potentially indicating confidence in the company’s future prospects and stability, which may positively influence stakeholder perceptions.

Paragon Care Announces Leadership Transition as Part of Growth Strategy

Paragon Care Limited announced that Mr. John Walstab will transition from his executive role to a Non-Executive Director position effective 1 April 2025. Mr. Walstab, who founded Quantum Healthcare and played a key role in its merger with Paragon Care, will continue to contribute his expertise to the company’s board. This transition is part of Paragon Care’s strategy to integrate CH2 and ParagonCare, enhancing its growth prospects in the Asia-Pacific region.